Differential Expression of the RANKL-RANK-OPG System Is Associated with Bone Metastasis in Human Non-Small Cell Lung CancerReport as inadecuate




Differential Expression of the RANKL-RANK-OPG System Is Associated with Bone Metastasis in Human Non-Small Cell Lung Cancer - Download this document for free, or read online. Document in PDF available to download.

Background

Human non-small cell lung cancer NSCLC patients exhibit a high propensity to develop skeletal metastasis, resulting in excessive osteolytic activity. The RANKL-RANK-OPG system, which plays a pivotal role in bone remodeling by regulating osteoclast formation and activity, is of potential interest in this context.

Materials and Methods

Reverse transcriptase polymerase chain reaction, western blotting, and immunohistochemical analysis were used to examine the expression of RANKL, RANK, and OPG in human NSCLC cell lines with different metastatic potentials, as well as in 52 primary NSCLC samples and 75 NSCLC bone metastasis samples. In primary NSCLC patients, the expression of these proteins was correlated with clinicopathological parameters. Recombinant human RANKL and transfected RANKL cDNA were added to the PAa cell line to evaluate the promoter action of RANKL during the process of metastasis in vitro and in vivo.

Results

Up-regulated RANKL, RANK, and OPG expression and increased RANKL:OPG ratio were detected in NSCLC cell lines and in tumor tissues with bone metastasis, and were correlated with higher metastatic potential. The metastatic potential of NSCLC in vitro and in vivo, including migration and invasion ability, was significantly enhanced by recombinant human RANKL and the transfection of RANKL cDNA, and was impaired after OPG was added. The increased expression of RANKL and OPG correlated with tumor stage, lymph node metastasis, and distant metastasis.

Conclusions

Differential expression of RANKL, RANK, and OPG is associated with the metastatic potential of human NSCLC to skeleton, raising the possibility that the RANKL-RANK-OPG system could be a therapeutic target for the treatment of metastatic NSCLC patients.



Author: Xianbo Peng, Wei Guo , Tingting Ren, Zhiyuan Lou, Xinchang Lu, Shuai Zhang, Qunshan Lu, Yifeng Sun

Source: http://plos.srce.hr/



DOWNLOAD PDF




Related documents